Juan Delgado-Cuesta

Prof. Juan Delgado-Cuesta

Internal Medicine, Hospital Universitario Virgen del Rocío, Seville, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2011 in AGE
Verified
Journal Article
Closed access
PDF file
SFSara Ferrando-Martínez
Sara Ferrando-Martínez
MRMaría Concepción Romero-Sánchez
María Concepción Romero-Sánchez
RSRafael Solana
Rafael Solana
JDJuan Delgado-Cuesta
Juan Delgado-Cuesta
RRRafael de la Rosa
Rafael de la Rosa
MLManuel Leal
Manuel Leal

1 November 1999 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
JDJuan Delgado-Cuesta
Juan Delgado-Cuesta
JMJ Macã­aS
J Macã­aS
JPJ A Pineda
J A Pineda
JCJ E Corzo
J E Corzo
MGM P Gonzã¡Lez-Moreno
M P Gonzã¡Lez-Moreno
JMJ Macías
J Macías
Organic pentavalent antimonials are one of the mainstays of treatment for visceral leishmaniasis (VL). Few data are available on the toxicity and efficacy of these drugs at the dosing schedule recommended by the Centers for Disease Control and Prevention (CDC) (Atlanta, GA). We analyzed 25 VL episodes in human immunodeficiency virus (HIV)-infected patients who were treated with meglumine antimoniate (MA) at the CDC-recommended dose in southern Spain. Adverse effects were observed in 14 (56%) VL episodes. In 7 (28%), treatment with MA was permanently discontinued due to serious adverse effects that included acute pancreatitis, acute renal failure, and leukopenia. Three (12%) patients died during therapy due to severe acute pancreatitis attributable to MA. The dosing regimen of MA currently recommended for treating VL is associated with a high rate of serious side effects in HIV-1-infected patients.

1 March 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
RRRafael de la Rosa
Rafael de la Rosa
JPJuan A Pineda
Juan A Pineda
JDJuan Delgado-Cuesta
Juan Delgado-Cuesta
JMJuan Macías
Juan Macías
FMFrancisco Morillas
Francisco Morillas
ELEduardo Lissen
Eduardo Lissen
The way in which the extensive use of highly active antiretroviral therapy (HAART) has influenced the incidence of visceral leishmaniasis (VL) among human immunodeficiency type 1 (HIV-1)-infected patients is not yet understood. The present study assessed whether the incidence of symptomatic VL in HIV-infected patients has decreased since the introduction of HAART. Likewise, the role of other potential risk factors for VL was also analyzed. Therefore, 479 HIV-1-infected patients receiving antiretroviral treatment, according to the available drugs at each moment, were prospectively followed from April 1989 to June 2000 in two university hospitals in southern Spain. A bone marrow aspiration was performed when patients showed symptoms suggestive of kala-azar. A diagnosis of VL was made whenLeishmaniaamastigotes were seen in Giemsa-stained samples or promastigotes were cultured in specific media. The median follow-up time was 1,380 [8 to 4,536] days. Twenty-one patients were diagnosed with symptomatic VL. The density of incidence of VL has decreased 64.8% as of January 1997, when HAART began to be used extensively in our area. The use of HAART was the main independent factor associated with VL; this therapy was a protective factor (adjusted hazard ratio [HR], 0.05; 95% confidence interval [CI], 0.02 to 0.15). CDC clinical category C at entry in the cohort (HR, 4.08; 95% CI, 1.46 to 11.35) and CD4+cell counts below 300 cells/mm3during the follow-up (HR, 3.96; 95% CI, 1.56 to 10.01) were also independently associated with kala-azar. A VL diagnosis prior to follow-up and low compliance with antiretroviral therapy were not independently associated with symptomatic VL, although statistical significance was almost reached (P= 0.1 andP= 0.08, respectively). In summary, the use of HAART has led to a fall in the incidence of symptomatic VL in HIV-infected patients. The main risk factor associated with kala-azar emergence in patients infected with HIV is deep immunosuppression.

1 February 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
GPGermán Peñalva
Germán Peñalva
RFRocío Fernández‐Urrusuno
Rocío Fernández‐Urrusuno
JTJosé María Turmo
José María Turmo
RHRocío Hernández-Soto
Rocío Hernández-Soto
IPIgnacio Pajares
Ignacio Pajares
JTJoaquín Torres-Moreno
Joaquín Torres-Moreno

9 July 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
RPR. S. De Pablo-Bernal
R. S. De Pablo-Bernal
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos
IRI. Rosado
I. Rosado
BDB. Dominguez-Molina
B. Dominguez-Molina
AAA. I. Alvarez-Rios
A. I. Alvarez-Rios
SFS. Ferrando-Martinez
S. Ferrando-Martinez
Chronic and systemic inflammatory alterations occur in HIV-infected patients and elderly uninfected subjects and in both scenarios these alterations are associated with the development of chronic morbidities and mortality. However, whether the levels of inflammatory alterations in untreated HIV-infected patients and elderly individuals are similar is unknown. Moreover, whether long-term antiretroviral therapy normalizes inflammatory alterations compared with HIV-uninfected persons of different age is not known. We analysed soluble inflammatory levels [high-sensitivity C-reactive protein, interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8 and IL-17] in a cohort of viraemic HIV-infected patients compared with (i) age-matched, (ii) elderly and (iii) non-survivor elderly, uninfected healthy controls. We longitudinally analysed the effect of long-term 48 and 96 week suppressive combined antiretroviral therapy (cART) on the soluble inflammatory levels compared with those found in control subjects. Baseline IL-6 and IL-8 levels were at similar or lower concentrations in untreated patients compared with healthy elderly individuals. However, TNF-α and IFN-γ levels broadly exceeded those found in survivors and non-survivor elderly individuals. Long-term suppressive cART normalized most of the inflammatory markers, with the exception of TNF-α levels, which persisted as high as those in elderly non-survivor controls. Chronic inflammatory alterations associated with HIV infection are maintained at a different level from those of ageing. The persistent alteration of TNF-α levels in HIV-infected patients might cause tissue damage and have implications for developing non-AIDS-defining illnesses, even when HIV replication is long-term controlled by cART.

1 November 2020 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
MBM. Bernabeu-Wittel
M. Bernabeu-Wittel
JTJ.E. Ternero-Vega
J.E. Ternero-Vega
PDP. Díaz-Jiménez
P. Díaz-Jiménez
CCC. Conde-Guzmán
C. Conde-Guzmán
NMNieto- Martín
Nieto- Martín
MOM. Ollero-Baturone
M. Ollero-Baturone